



Innovative Molecules Announces Completion of Phase 1 Program and Advancement to Phase 2 for Oral Adibelivir

Descrizione

COMUNICATO STAMPA - CONTENUTO PROMOZIONALE

MUNICH, Jan. 29, 2026 /PRNewswire/ - Innovative Molecules GmbH, a German clinical stage biotech company focused on development of novel agents in the field of herpes-mediated diseases, today announced the successful completion of its Phase 1 clinical development program and the transition into Phase 2 for its oral selective helicase primase HSV inhibitor adibelivir (IM-250).

The Phase 1 clinical development program included the following clinical trials:

Across these studies, oral adibelivir demonstrated a clinical profile that supports advancement into the Phase 2a, efficacy-focused part of the IM-202 trial.

CEO, Innovative Molecules, Florian Vogel said: "With the successful completion of our Phase 1 program, we have achieved a critical development milestone for adibelivir. This validates our clinical strategy and forms a strong foundation for transition into the next stage of clinical development."

About Innovative Molecules

Innovative Molecules GmbH is a biotechnology company based in Munich, Germany, focused on developing transformative therapies for herpes infections. Its pipeline is dedicated to advancing novel antivirals that address severe and underserved patient populations. Current lead program is the development of adibelivir (IM-250), a novel selective helicase primase inhibitor for the treatment of Herpes simplex (HSV) mediated diseases.

Logo: https://mma.prnewswire.com/media/2711617/Innovative_Molecules_Logo.jpg

View original content to download multimedia:<https://www.prnewswire.co.uk/news-releases/innovative-molecules-announces-completion-of-phase-1-program-and-advancement-to-phase-2-for-oral-adibelivir-302673920.html>

Copyright 2026 PR Newswire. All Rights Reserved.

COMUNICATO STAMPA â?? CONTENUTO PROMOZIONALE: Immediapress Ã? un servizio di diffusione di comunicati stampa in testo originale redatto direttamente dallâ??ente che lo emette. Lâ??Adnkronos e Immediapress non sono responsabili per i contenuti dei comunicati trasmessi

â??

immediapress

Categoria

1. Comunicati

Tag

1. ImmediaPress

Data di creazione

Gennaio 29, 2026

Autore

redazione

default watermark